HealthMore in Health→
Novartis Wants More From Avidity Than Muscular Dystrophy Alone
Key Takeaways
- Novartis says Avidity’s science may have uses beyond muscular dystrophies.
- The company tied that view to extracting more value from its $12 billion acquisition.
- The supplied material does not identify specific new disease targets or timelines.
DE
DT Editorial Team··via endpoints.news
